Add Formweb to your mobile device
Approved Formulary
Search results for:
dantrolene
dantrolene
Brand names: Dantrium, Revonto
| Form | Strength |
|---|---|
| CAPSULE, ORAL | 25 mg |
| POWDER FOR INJECTION, INTRAVENOUS | 20 mg |
Display Direct Acting Skeletal Muscle Relaxants Class:
122008
Medication comments:
| Adult Extravasation Management | ||
|---|---|---|
| dantrolene (Dantrium, Revonto, Ryanodex) | ||
| Agent type: | Non-Chemotherapeutic |
| Vesicant/Irritant: | |
| Local Care: | None |
| Antidote: | No known antidote |
| 2023 American Geriatrics Society Beers Criteria® for potentially inappropriate medication use in older adults. | |
|---|---|
| Medication: | dantrolene (Dantrium) |
| Criteria 4: Potentially clinically important drug-drug interactions that should be avoided in older adults. (Table 5) | |
| Interacting drug(s) or class(es) | skeletal muscle relaxants ⇄ CNS-active agents |
| Risk Rationale | Increased risk of falls and of fracture with the concurrent use of ≥3 CNS-active agents (antiepileptics including gabapentinoids, antidepressants, antipsychotics, benzodiazepines, Nonbenzodiazepine benzodiazepine receptor agonist hypnotics, opioids, and skeletal muscle relaxants). |
| Recommendation | Avoid concurrent use of ≥3 CNS-active drugs Click for list; minimize the number of CNS-active drugs. |
| Quality of evidence: High, Strength of Recommendation: Strong | |
Last updated: Sep. 18, 2025
- Black Box Warnings Hepatotoxicity